Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Stock Information for Insight Molecular Diagnostics Inc Com (New)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Insight Molecular Diagnostics Inc Com (New)

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology
Oncocyte Reports Q1 2025 Results and Business Progress
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Oncocyte Provides Positive Update on Clinical Trial Progress
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.